These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells. Accardo-Palumbo A; Triolo G; Colonna-Romano G; Potestio M; Carbone M; Ferrante A; Giardina E; Caimi G; Triolo G Diabetologia; 2000 Aug; 43(8):1039-47. PubMed ID: 10990082 [TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986 [TBL] [Abstract][Full Text] [Related]
5. [Complement regulatory factors and immunologic recognition mechanism between species]. Seya T; Matsunoto M Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):637-42. PubMed ID: 8963770 [No Abstract] [Full Text] [Related]
7. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. Tedesco F; Narchi G; Radillo O; Meri S; Ferrone S; Betterle C J Immunol; 1993 Aug; 151(3):1562-70. PubMed ID: 7687635 [TBL] [Abstract][Full Text] [Related]
8. Glomerulonephritis and complement regulatory proteins. Nangaku M; Johnson RJ; Couser WG Exp Nephrol; 1997; 5(5):345-54. PubMed ID: 9386969 [No Abstract] [Full Text] [Related]
14. Complement regulatory molecules: application to therapy and transplantation. Morgan BP Immunol Today; 1995 Jun; 16(6):257-9. PubMed ID: 7544975 [No Abstract] [Full Text] [Related]
15. Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C; van Denderen B; Adam B; Aminian A; Allison J; Pearse M; d'Apice A Transplant Proc; 1995 Dec; 27(6):3565-6. PubMed ID: 8540103 [No Abstract] [Full Text] [Related]
16. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy. Ravindranath NM; Nishimoto K; Chu K; Shuler C Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630 [TBL] [Abstract][Full Text] [Related]
17. [Research progression on complement regulatory proteins CD46, CD55, and CD59 in tumor immunotherapy]. Qin C; Cai XY Ai Zheng; 2006 Nov; 25(11):1450-3. PubMed ID: 17094920 [TBL] [Abstract][Full Text] [Related]
18. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270 [TBL] [Abstract][Full Text] [Related]
19. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. Harrower TP; Richards A; Cruz G; Copeman L; Dunnett SB; Barker RA Xenotransplantation; 2004 Jan; 11(1):60-71. PubMed ID: 14962294 [TBL] [Abstract][Full Text] [Related]
20. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Simpson KL; Jones A; Norman S; Holmes CH Am J Pathol; 1997 Nov; 151(5):1455-67. PubMed ID: 9358772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]